Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2011-06-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
第四届董事会第十九次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of Beijing SL Pharmaceutical Co., Ltd. It details resolutions passed at the 19th extraordinary meeting of the 4th board, including approval of a significant equity transfer and the scheduling of an extraordinary shareholders' meeting. The content focuses on board decisions and meeting outcomes rather than full financial data or detailed reports. The document length is short (975 characters), and it is an announcement of board meeting resolutions, not a full report or financial statement. Therefore, it fits best under 'Board/Management Information' (MANG), which covers announcements of changes or decisions by the board or senior management.
2011-06-17 Chinese
关于出让参股公司北京普仁鸿医药销售有限公司部份股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the sale of a portion of equity in a subsidiary company (Beijing Purenhong Pharmaceutical Sales Co., Ltd.) by Beijing Shuanglu Pharmaceutical Co., Ltd. It details the transaction overview, parties involved, financial data of the subsidiary, terms of the equity transfer agreement, and the impact on the parent company. The document includes financial figures but primarily focuses on the transaction details and shareholder meeting requirements for approval. It is not a full financial report, audit report, or earnings release. It is a formal announcement of a capital transaction involving share transfer and strategic cooperation, fitting the category of Capital/Financing Update (CAP).
2011-06-17 Chinese
北京普仁鸿医药销售有限公司2010年度财务报表及审计报告
Audit Report / Information Classification · 95% confidence The document is titled "北京普仁鸿医药销售有限公司 2010 年度财务报表及审计报告" which translates to "Beijing Purenhong Pharmaceutical Sales Co., Ltd. 2010 Annual Financial Statements and Audit Report." It contains detailed financial statements including balance sheet, income statement, cash flow statement, and extensive notes to the financial statements. The document also includes an auditor's report from PwC, which provides an audit opinion on the financial statements for the fiscal year ended December 31, 2010. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. The presence of the auditor's report along with the full financial statements indicates this is a standalone audit report document rather than a full annual report or other filing. Therefore, the document fits the definition of an Audit Report / Information (AR). FY 2010
2011-06-17 Chinese
关于召开2011年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2011 first extraordinary general meeting of shareholders for Beijing Shuanglu Pharmaceutical Co., Ltd. It includes details such as meeting time, location, agenda, registration methods, and proxy forms. There is no financial data, earnings, or report content. It is an announcement informing shareholders about the meeting and how to participate, not the report or results of the meeting itself. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2011-06-17 Chinese
北京市君泽君律师事务关于公司股票期权激励计划相关激励对象行权的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the stock option incentive plan and the exercise of stock options by a specific individual (徐明波) at Beijing SL Pharmaceutical Co., Ltd. It references various legal and regulatory frameworks, company board and supervisory meetings, and compliance with stock option plan conditions. The document is a standalone legal opinion focused on the legality and compliance of stock option exercises, not a financial report, earnings release, or general announcement. It does not contain financial statements or management discussion but is a legal certification related to stock option exercises. Therefore, it fits best under the category of Regulatory Filings (RNS), which includes legal opinions and compliance documents that do not fit other specific categories.
2011-05-17 Chinese
股权激励行权导致公司第一大股东变更的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding a change in the company's largest shareholder due to the exercise of stock options by the general manager, including details about shareholding percentages and lock-up periods. It references the company's stock option incentive plan and related regulatory provisions. The document is short (1236 characters) and focuses on ownership changes rather than financial results or detailed reports. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2011-05-17 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.